Answers are grounded in this paper and cite their sources.
Case report shows high 18F-FGln uptake in meningiomas, indicating potential for improved diagnosis and treatment.
A 64-year-old woman with persistent headaches and vision disturbances underwent 18F-(2S,4R)-4-fluoroglutamine (18F-FGln) PET/CT due to MRI contraindications. Imaging revealed a sellar mass with high radiotracer uptake (SUVmax 7.17), later confirmed as a WHO grade I meningioma. This case highlights the potential of 18F-FGln PET/CT in detecting meningiomas, leveraging their glutamine metabolism. Given the tumor's metabolic profile, glutaminase inhibitors may offer novel therapeutic avenues. Further research is warranted to explore the mechanistic basis of 18F-FGln uptake in meningiomas and its implications for diagnosis and treatment.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: